title: Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation.
authors.forename: S
authors.initials: S
authors.lastname: Wahie
authors.forename: A
authors.initials: A
authors.lastname: Alexandroff
authors.forename: N J
authors.initials: NJ
authors.lastname: Reynolds
authors.forename: S J
authors.initials: SJ
authors.lastname: Meggit
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011565:Psoriasis / Q000209:etiology* / Q000276:immunology; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone